Wragge advises AstraZeneca on Lilly alliance to develop Alzheimer’s inhibitor
Wragge Lawrence Graham & Co has advised AstraZeneca on its alliance with Lilly to develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. Wragge Lawrence Graham & Co supported the Boston-based chief counsel of AstraZeneca Neuroscience, Conor Johnston. The law firm’s specialist […]